China SXT Pharmaceuticals (SXTC) Current Deferred Revenue (2018 - 2026)
China SXT Pharmaceuticals (SXTC) posted quarterly Current Deferred Revenue of $104423.0 for Q1 2026, up 78.11% year-on-year from $58627.0 in Q1 2025, and up 60.51% on a QoQ basis from $65057.0 in Q3 2025.
China SXT Pharmaceuticals (SXTC) Current Deferred Revenue (2018 - 2026) Analysis & Trends
China SXT Pharmaceuticals (SXTC) has reported Current Deferred Revenue for 9 consecutive years, with $104423.0 the latest figure, recorded in Q1 2026.
- Quarterly Current Deferred Revenue rose 78.11% year-over-year to $104423.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104423.0 (up 78.11% YoY) and the FY2026 annual result came in at $104423.0, up 78.11% from the prior year.
- Current Deferred Revenue advanced to $104423.0 in Q1 2026 per SXTC's latest filing, from $65057.0 in the prior quarter.
- Over the last five years, Current Deferred Revenue for SXTC reached as high as $190340.0 in Q3 2024 and fell as low as $58627.0 in Q1 2025.
- A 5-year average of $122700.7 and a median of $104423.0 in 2026 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue plunged 70.23% — and 2023, when it soared 192.15%.
- Year by year, Current Deferred Revenue stood at $65101.0 in 2022, then surged by 192.15% to $190193.0 in 2023, then climbed by 0.08% to $190340.0 in 2024, then slumped by 65.82% to $65057.0 in 2025, then surged by 60.51% to $104423.0 in 2026.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $104423.0, $65057.0, and $58627.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | China SXT Pharmaceuticals | 7.11 Mn | -21.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 104,423.00 |
| Sep 30, 2025 | 65,057.00 |
| Mar 31, 2025 | 58,627.00 |
| Sep 30, 2024 | 190,340.00 |
| Mar 31, 2024 | 187,665.00 |
| Sep 30, 2023 | 190,193.00 |
| Mar 31, 2023 | 165,534.00 |
| Sep 30, 2022 | 65,101.00 |
| Mar 31, 2022 | 77,366.00 |
| Sep 30, 2021 | 218,644.00 |
| Mar 31, 2021 | 257,449.00 |
| Sep 30, 2020 | 217,412.00 |
| Mar 31, 2020 | 298,042.00 |
| Sep 30, 2019 | 120,575.00 |
| Mar 31, 2019 | 57,553.00 |
| Sep 30, 2018 | 117,992.00 |
| Mar 31, 2018 | 292,947.00 |